Income Statement

v3.8.0.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue:    
Grant and licensing revenue $ 752,527 $ 24,240
Operating expenses:    
Research and development 2,872,950 1,812,901
General and administrative 1,780,339 1,527,015
Change in fair value of contingent consideration 11,118
Total operating expenses 4,664,407 3,339,916
Loss from operations (3,911,880) (3,315,676)
Interest income 3,633 5,221
Other income, net 175,020 69,727
Total non-operating income, net 178,653 74,948
Net loss (3,733,227) (3,240,728)
Net loss - non-controlling interest (206,461) (50,791)
Net loss attributable to Heat Biologics, Inc. $ (3,526,766) $ (3,189,937)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.75) $ (1.18)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 4,709,553 2,695,762
Other comprehensive loss:    
Net loss $ (3,733,227) $ (3,240,728)
Unrealized gain (loss) on foreign currency translation 21,325 (66,375)
Total other comprehensive loss (3,711,902) (3,307,103)
Comprehensive loss attributable to non-controlling interest (206,461) (50,791)
Comprehensive loss $ (3,505,441) $ (3,256,312)

Source